MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 528420 | Name: DuP-532

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DuP-532, also known as L-694492, is an angiotensin type 1 receptor antagonist potentially for the treatment of hypertension and heart failure.

Chemical Structure

DuP-532
DuP-532
CAS#124750-95-4

Theoretical Analysis

MedKoo Cat#: 528420

Name: DuP-532

CAS#: 124750-95-4

Chemical Formula: C23H19F5N6O2

Exact Mass: 506.1490

Molecular Weight: 506.44

Elemental Analysis: C, 54.55; H, 3.78; F, 18.76; N, 16.59; O, 6.32

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
DuP-532; DuP 532; DuP532; L-694492; L694492; L 694492
IUPAC/Chemical Name
1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(perfluoroethyl)-2-propyl-1H-imidazole-5-carboxylic acid
InChi Key
RQGDXPDTZWGCQI-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H19F5N6O2/c1-2-5-17-29-19(22(24,25)23(26,27)28)18(21(35)36)34(17)12-13-8-10-14(11-9-13)15-6-3-4-7-16(15)20-30-32-33-31-20/h3-4,6-11H,2,5,12H2,1H3,(H,35,36)(H,30,31,32,33)
SMILES Code
O=C(C1=C(C(F)(F)C(F)(F)F)N=C(CCC)N1CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 506.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Maillard MP, Centeno C, Frostell-Karlsson Å, Brunner HR, Burnier M. Does protein binding modulate the effect of angiotensin II receptor antagonists? J Renin Angiotensin Aldosterone Syst. 2001 Mar;2(1_suppl):S54-S58. doi: 10.1177/14703203010020010901. PubMed PMID: 28095232. 2: Maurin MB, Taylor A. Variable heating rate thermogravimetric analysis as a mechanism to improve efficiency and resolution of the weight loss profiles of three model pharmaceuticals. J Pharm Biomed Anal. 2000 Nov;23(6):1065-71. PubMed PMID: 11095309. 3: De Witt BJ, Garrison EA, Champion HC, Kadowitz PJ. L-163,491 is a partial angiotensin AT(1) receptor agonist in the hindquarters vascular bed of the cat. Eur J Pharmacol. 2000 Sep 15;404(1-2):213-9. PubMed PMID: 10980281. 4: Champion HC, Estrada LS, Estrada LN, Filep JG, Kadowitz PJ. Analysis of effects of bosentan (Ro 47-0203), a nonpeptide endothelin ETA/ETB receptor antagonist, in the hind-limb vascular bed of the cat. Can J Physiol Pharmacol. 1998 Feb;76(2):141-7. PubMed PMID: 9635152. 5: Garrison EA, Champion HC, Kadowitz PJ. [Pro11,D-Ala12]angiotensin I has rapid onset vasoconstrictor activity in the cat. Am J Physiol. 1997 Dec;273(6 Pt 1):E1059-64. PubMed PMID: 9435519. 6: Walsh DA, Hu DE, Wharton J, Catravas JD, Blake DR, Fan TP. Sequential development of angiotensin receptors and angiotensin I converting enzyme during angiogenesis in the rat subcutaneous sponge granuloma. Br J Pharmacol. 1997 Apr;120(7):1302-11. PubMed PMID: 9105706; PubMed Central PMCID: PMC1564611. 7: Goldberg MR, Lo MW, Christ DD, Chiou R, Furtek CI, Amit O, Carides A, Biollaz J, Piguet V, Nussberger J, Brunner HR. DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan. Clin Pharmacol Ther. 1997 Jan;61(1):59-69. PubMed PMID: 9024174. 8: Garrison EA, Kadowitz PJ. Analysis of responses to angiotensin I-(3-10) in the hindlimb vascular bed of the cat. Am J Physiol. 1996 Apr;270(4 Pt 2):H1172-7. PubMed PMID: 8967354. 9: Kaye AD, Nossaman BD, Kivlighn S, Ibrahim IN, De Witt BJ, Kadowitz PJ. Responses to L-163,491, a nonpeptide angiotensin II mimic, in the pulmonary vascular bed of the cat. Eur J Pharmacol. 1995 Dec 12;287(2):163-8. PubMed PMID: 8749030. 10: Corriu C, Bernard S, Schott C, Stoclet JC. Effects of losartan on contractile responses of conductance and resistance arteries from rats. J Cardiovasc Pharmacol. 1995 Nov;26(5):688-92. PubMed PMID: 8637181. 11: Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs. Arch Intern Med. 1995 Jul 10;155(13):1361-8. Review. PubMed PMID: 7794084. 12: Pelet C, Mironneau C, Rakotoarisoa L, Neuilly G. Angiotensin II receptor subtypes and contractile responses in portal vein smooth muscle. Eur J Pharmacol. 1995 Jun 6;279(1):15-24. PubMed PMID: 7556378. 13: Garrison EA, Santiago JA, Osei SY, Kadowitz PJ. Analysis of responses to angiotensin peptides in the hindquarters vascular bed of the cat. Am J Physiol. 1995 Jun;268(6 Pt 2):H2418-25. PubMed PMID: 7611494. 14: Owen RA, Molon-Noblot S, Hubert MF, Kindt MV, Keenan KP, Eydelloth RS. The morphology of juxtaglomerular cell hyperplasia and hypertrophy in normotensive rats and monkeys given an angiotensin II receptor antagonist. Toxicol Pathol. 1995 May-Jun;23(3):606-19. PubMed PMID: 7659963. 15: Beauchamp HT, Chang RS, Siegl PK, Gibson RE. In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency. J Pharmacol Exp Ther. 1995 Feb;272(2):612-8. PubMed PMID: 7853174. 16: Nekooeian AA, Ogilvie RI, Zborowska-Sluis D. Acute hemodynamic effects of drugs acting on the renin-angiotensin system in acute heart failure. Can J Cardiol. 1995 Jan;11(1):59-64. PubMed PMID: 7850666. 17: Kaye AD, Nossaman BD, Margolis MA, Ibrahim IN, Kivlighn SD, Smith DE, Kadowitz PJ. Responses to a nonpeptide angiotensin receptor agonist, L 163491, in the feline pulmonary vascular bed. Life Sci. 1995;57(20):PL301-5. PubMed PMID: 7475924. 18: Owen RA, Molon-Noblot S, Hubert MF, Kindt MV, Keenan KP, Eydelloth RS. The morphology of juxtaglomerular cell hyperplasia and hypertrophy in normotensive rats and monkeys given an angiotensin II receptor antagonist. Toxicol Pathol. 1994 Nov-Dec;22(6):606-19. Corrected and republished in: Toxicol Pathol. 1995 May-Jun;23(3):606-19. PubMed PMID: 7732278. 19: Cheng DY, DeWitt BJ, Dent EL, Nossaman BD, Kadowitz PJ. Analysis of responses to angiotensin IV in the pulmonary vascular bed of the cat. Eur J Pharmacol. 1994 Aug 11;261(1-2):223-7. PubMed PMID: 8001649. 20: Cheng DY, DeWitt BJ, McMahon TJ, Kadowitz PJ. Comparison of pressor responses to angiotensin I, II, and III in pulmonary vascular bed of cats. Am J Physiol. 1994 Jun;266(6 Pt 2):H2247-55. PubMed PMID: 8023987.

View History

Maraviroc

Maraviroc

Featured